Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks make headway amid weak China data

Mon, 15th Aug 2022 17:00

(Alliance News) - Stocks in London struggled on Monday, but managed to end higher, even as China's central bank slashed key interest rates as a raft of data showed weakness in the world's second-largest economy.

The PBoC on Monday sliced the medium-term lending rate to 2.75%, a reduction of 10 basis points. The interest rate is used a benchmark for one-year loans provided to the banking system.

The move came after factory output and retail sales in China edged up in July but were weaker than analysts' expectations, as a Covid-19 resurgence and property market jitters cast a pall over hopes for a stronger economic recovery.

The world's second-biggest economy saw a bounce in business activity as some coronavirus restrictions eased in June, but the boost is fading and Beijing remains welded to a zero-Covid policy of snap lockdowns and long quarantines, which has battered sentiment.

But for July, China's industrial production rose 3.8% on-year, down from a 3.9% jump in June, the National Bureau of Statistics said Monday. This undershot market expectations, cited by FXStreet, for growth to speed up to 4.6%.

Retail sales grew at a slower-than-expected 2.7% from a year ago, down from 3.1% in June, while the urban unemployment rate fell to 5.4%, the NBS said. Retail sales had been expected to rise 5%, cited by FXStreet.

The FTSE 100 index closed up 8.26 points, or 0.1%, at 7,509.15. The FTSE 250 closed up 43.80 points, or 0.2%, at 20,382.76, and the AIM All-Share closed up 0.91 of a point at 934.11.

The Cboe UK 100 ended up 0.1% at 749.94. The Cboe UK 250 closed down 0.1% at 17,684.28. The Cboe Small Companies ended flat at 14,472.95.

In European equities, the CAC 40 in Paris ended up 0.3%, while the DAX 40 in Frankfurt ended up 0.2%.

CMC Markets analyst Michael Hewson said: "Basic resources and energy sector have borne the brunt of today's uncertainty after [China's] July industrial production and retail sales both came in well below expectations. The bigger surprise is why anyone is surprised by this given China's reluctance to relax its zero-covid policy, a policy that is likely to weigh on economic growth even more as we head into the winter months.

"As the weather gets colder it's unlikely that infection rates will go down, which means economic activity is likely to remain subdued, and consumer demand will remain weak. In response to today's data China's central bank cut its medium-term lending rate by 10bps, to 2.75%, in a vain attempt to stimulate demand."

In the FTSE 100, RS Group ended the best performer, up 5.0% at 1,142.38 pence, after the Times reported at the weekend that the electrical parts maker could be the subject of a takeover bid.

The Times reported that there has been "chat" that there may be a GBP15-a-share bid imminently. This would be a significant premium to the present price and above the GBP12.35 high the company, formerly known as Electrocomponents, hit last November before worries about recession surfaced.

However, the report did not name any potential suitor.

AstraZeneca closed up 2.2% after it said, alongside partner Daiichi Sankyo, that their Enhertu drug met its primary endpoint in a breast cancer trial.

The Cambridge-based pharmaceutical firm said a form of breast cancer in patients treated with Enhertu showed slowed disease progression. The trial involved sufferers of human epidermal growth factor receptor 2-positive unresectable and/or metastatic breast cancer. Participants had been previously treated with trastuzumab emtansine, an existing cancer therapy.

At the other end of the large-caps, miners were among the worst performers following the disappointing China data. Antofagasta closed down 1.5%, Anglo American down 2.4%, Rio Tinto down 2.2% and Glencore down 1.4%.

Meanwhile, Rio Tinto reiterated its proposal to acquire full-ownership of Turquoise Hill Resources for CAD34 per share, around USD25.48.

The announcement comes after Turquoise Hill said earlier in the day that it was no longer considering Rio Tinto's takeover offer. The Canadian miner said Rio Tinto's offer did not "fully and fairly reflect the fundamental and long-term strategic value" of its majority ownership in the Oyu Tolgoi copper-gold project in Mongolia.

As a result, the company said it was not in the best interest of the company or its shareholders to support Rio Tinto's proposal. Rio Tinto said it was "disappointed" by the decision and asserted that the terms of its proposal would deliver "compelling value" for Turquoise Hill.

In March, the FTSE 100-listed miner announced it was proposing to acquire the remaining 49% of Turquoise Hill that it does not currently own. This represented a 32% premium to the firm's closing price on the Toronto Stock Exchange at the time.

Oil majors BP and Shell closed down 1.2% and 1.5% respectively, tracking spot oil prices lower.

Brent oil was quoted at USD94.22 a barrel at the equities close, down sharply from USD97.91 at the close Friday.

In the FTSE 250, Auction Technology ended the worst performer, down 4.7%, after JPMorgan downgraded the platform to 'neutral' from 'overweight'.

The pound was quoted at USD1.2075 at the London equities close, down from USD1.2121 at the close Friday.

The euro stood at USD1.0184 at the European equities close, down from USD1.0248. Against the yen, the dollar was trading at JPY133.07, down from JPY133.63.

Stocks in New York were lower at the London equities close. The DJIA was down 0.1%, the S&P 500 index down 0.3% and the Nasdaq Composite down 0.2%.

On Wall Street, Moderna was up 2.5% after the UK's medicines regulator said it had approved an updated version of the drugmaker's vaccine against Covid-19, that targets the Omicron variant as well as the original form of the virus.

The Medicine & Healthcare products Regulatory Agency said it had approved the vaccine for adult booster doses "after it was found to meet the UK regulator's standards of safety, quality and effectiveness".

It was the first such "bivalent" Covid-19 vaccine to be approved by the UK regulator.

Gold stood at USD1,778.71 an ounce at the London equities close, lower against USD1,797.13 late Friday.

The economic events calendar on Tuesday has UK unemployment data at 0700 BST and Germany ZEW indicator of economic sentiment at 1000 BST.

The UK corporate calendar on Tuesday has annual results from miner BHP Group and interim results from Bank of Georgia. Authorised Rolex dealer Watches of Switzerland puts out first-quarter numbers.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.